CapsoVision Announces Pricing of Initial Public Offering
CapsoVision (NASDAQ: CV), a commercial-stage medical technology company specializing in advanced imaging and AI-powered capsule endoscopy solutions, has announced the pricing of its initial public offering (IPO). The company is offering 5,500,000 shares of common stock at $5.00 per share.
Trading is set to commence on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol "CV". The offering, expected to close on July 3, 2025, aims to raise approximately $27.5 million in gross proceeds before deducting underwriting costs and other expenses. The underwriters have a 30-day option to purchase up to 825,000 additional shares at the IPO price.
The Benchmark Company and Roth Capital Partners are serving as joint book-running managers for the offering, which will be conducted through a prospectus as part of an SEC-approved registration statement.
CapsoVision (NASDAQ: CV), un'azienda tecnologica medica in fase commerciale specializzata in soluzioni avanzate di imaging e capsula endoscopica potenziata da intelligenza artificiale, ha annunciato il prezzo della sua offerta pubblica iniziale (IPO). La società offre 5.500.000 azioni ordinarie al prezzo di 5,00 $ per azione.
Le negoziazioni inizieranno sul Nasdaq Capital Market il 2 luglio 2025, con il simbolo di borsa "CV". L'offerta, che si prevede si chiuderà il 3 luglio 2025, punta a raccogliere circa 27,5 milioni di dollari di proventi lordi prima delle spese di sottoscrizione e altri costi. I sottoscrittori hanno un'opzione di 30 giorni per acquistare fino a 825.000 azioni aggiuntive al prezzo dell'IPO.
The Benchmark Company e Roth Capital Partners agiscono come co-responsabili del collocamento per l'offerta, che sarà condotta tramite un prospetto nell'ambito di una dichiarazione di registrazione approvata dalla SEC.
CapsoVision (NASDAQ: CV), una empresa de tecnología médica en etapa comercial especializada en soluciones avanzadas de imagen y cápsula endoscópica impulsada por inteligencia artificial, ha anunciado el precio de su oferta pública inicial (IPO). La compañía ofrece 5.500.000 acciones ordinarias a 5,00 $ por acción.
La negociación comenzará en el Nasdaq Capital Market el 2 de julio de 2025, bajo el símbolo bursátil "CV". Se espera que la oferta cierre el 3 de julio de 2025, con el objetivo de recaudar aproximadamente 27,5 millones de dólares en ingresos brutos antes de deducir costos de suscripción y otros gastos. Los suscriptores tienen una opción de 30 días para comprar hasta 825.000 acciones adicionales al precio de la IPO.
The Benchmark Company y Roth Capital Partners actúan como gestores conjuntos principales de la oferta, que se realizará mediante un prospecto como parte de una declaración de registro aprobada por la SEC.
CapsoVision (NASDAQ: CV)는 첨단 영상 및 AI 기반 캡슐 내시경 솔루션을 전문으로 하는 상업 단계 의료 기술 회사로, 기업공개(IPO) 가격을 발표했습니다. 회사는 보통주 5,500,000주를 주당 5.00달러에 제공합니다.
거래는 2025년 7월 2일 나스닥 캐피털 마켓에서 "CV"라는 티커 심볼로 시작될 예정입니다. 이번 공모는 2025년 7월 3일 종료될 예정이며, 인수 비용 및 기타 비용을 제외하기 전 약 2,750만 달러의 총수익을 목표로 합니다. 인수단은 IPO 가격으로 최대 825,000주 추가 매입 권리를 30일간 보유합니다.
The Benchmark Company와 Roth Capital Partners가 공동 주관사로서 이번 공모를 진행하며, SEC 승인 등록서류의 일부인 투자설명서를 통해 진행됩니다.
CapsoVision (NASDAQ : CV), une entreprise technologique médicale en phase commerciale spécialisée dans l'imagerie avancée et les solutions d'endoscopie par capsule alimentées par l'IA, a annoncé le prix de son offre publique initiale (IPO). La société propose 5 500 000 actions ordinaires au prix de 5,00 $ par action.
La cotation débutera sur le Nasdaq Capital Market le 2 juillet 2025, sous le symbole "CV". L'offre, qui devrait se clôturer le 3 juillet 2025, vise à lever environ 27,5 millions de dollars de produit brut avant déduction des frais de souscription et autres dépenses. Les souscripteurs disposent d'une option de 30 jours pour acheter jusqu'à 825 000 actions supplémentaires au prix de l'IPO.
The Benchmark Company et Roth Capital Partners agissent en tant que co-chefs de file pour cette offre, qui sera menée via un prospectus dans le cadre d'une déclaration d'enregistrement approuvée par la SEC.
CapsoVision (NASDAQ: CV), ein medizinisches Technologieunternehmen in der kommerziellen Phase, das sich auf fortschrittliche Bildgebung und KI-gestützte Kapselendoskopielösungen spezialisiert hat, hat die Preisfestsetzung seines Börsengangs (IPO) bekannt gegeben. Das Unternehmen bietet 5.500.000 Stammaktien zum Preis von 5,00 USD pro Aktie an.
Der Handel soll am 2. Juli 2025 am Nasdaq Capital Market unter dem Tickersymbol "CV" beginnen. Das Angebot, das voraussichtlich am 3. Juli 2025 abgeschlossen wird, soll vor Abzug von Underwriting-Gebühren und anderen Kosten etwa 27,5 Millionen USD Bruttoerlös einbringen. Die Underwriter haben eine 30-tägige Option, bis zu 825.000 zusätzliche Aktien zum IPO-Preis zu erwerben.
The Benchmark Company und Roth Capital Partners fungieren als gemeinsame Bookrunner für das Angebot, das über einen Prospekt im Rahmen einer von der SEC genehmigten Registrierung durchgeführt wird.
- Expected to raise $27.5 million in gross proceeds from the IPO
- Listing on a major exchange (Nasdaq Capital Market)
- 30-day option for underwriters to purchase additional 825,000 shares indicates confidence in demand
- Relatively small IPO size may limit institutional investor interest
- Low share price of $5.00 could suggest limited market valuation
Insights
CapsoVision's $27.5M IPO brings a commercial-stage medical imaging company to Nasdaq at $5.00 per share.
CapsoVision has announced the pricing of its initial public offering on the Nasdaq Capital Market. The company is offering 5,500,000 shares of common stock at $5.00 per share, with trading expected to commence on July 2, 2025, under the ticker symbol "CV." The offering should generate
The IPO structure includes a standard 30-day option granted to underwriters to purchase up to an additional 825,000 shares at the initial offering price. This overallotment provision, commonly known as a "greenshoe option," allows underwriters to stabilize the stock price following the initial listing.
As a commercial-stage company focusing on advanced imaging and AI technologies for capsule endoscopy solutions, CapsoVision has positioned itself at the intersection of medical device technology and artificial intelligence. The mid-tier investment banks The Benchmark Company and Roth Capital Partners are serving as joint book-running managers, which is consistent with the offering size.
The successful registration with the SEC (declared effective on July 1) represents an important milestone in the company's development, providing access to public capital markets. While this offering size is relatively modest compared to larger medical technology IPOs, it potentially provides CapsoVision with additional capital to support its existing commercial operations.
SARATOGA, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of
CapsoVision has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, are expected to be approximately
The Benchmark Company, LLC and Roth Capital Partners are acting as joint book-running managers for the offering.
A registration statement on Form S-1 relating to the shares was declared effective by the U.S. Securities and Exchange Commission (SEC) on July 1, 2025. The offering is being made only by means of a prospectus forming a part of such registration statement. Copies of the final prospectus, when available, may be obtained from The Benchmark Company, LLC, 150 East 58th Street, 17th Floor, New York, NY 10155, Attention: Prospectus Department, or by email at prospectus@benchmarkcompany.com
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and diagnosis of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements related to the expected trading of CapsoVision’s common stock on the Nasdaq Capital Market and the anticipated closing of the offering. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, market conditions, the satisfaction of customary closing conditions related to the initial public offering, and other risks described in the Company’s registration statement on Form S-1 filed with the SEC. Forward-looking statements speak only as of the date of this press release, and CapsoVision undertakes no obligation to update or revise these statements, except as required by law.
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
Investors@CapsoVision.com
Kevin Lundquist
Chief Financial Officer, CapsoVision, Inc.
kml@capsovision.com
Media Contact
Leslie Strickler and Paul Spicer
Être Communications
leslies@etrecommunications.com | (804) 240-0807
pauls@etrecommunications.com | (804) 503-9231
FAQ
What is the IPO price for CapsoVision (NASDAQ: CV) stock?
When will CapsoVision (CV) stock start trading on Nasdaq?
How much money is CapsoVision (CV) raising in its IPO?
Who are the underwriters for CapsoVision's IPO?
What does CapsoVision (CV) company do?
